This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Heusch, G. Articles by Rimoldi, O. Search for Related Content PubMed PubMed Citation Articles by Heusch, G. Articles by Rimoldi, O. Related Collections Acute coronary syndromes Autonomic, reflex, and neurohumoral control of circulation Coronary circulation

(Circulation. 2000;101:689.)
© 2000 American Heart Association, Inc.

From Bench to Bedside

-Adrenergic Coronary Vasoconstriction and Myocardial Ischemia in Humans

Gerd Heusch, MD, FESC; Dietrich Baumgart, MD; Paolo Camici, MD, FESC; William Chilian, PhD; Luisa Gregorini, MD, FESC; Otto Hess, MD, FESC; Ciro Indolfi, MD; Ornella Rimoldi, MD

From Abteilung für Pathophysiologie (G.H.) and Abteilung für Kardiologie (D.B.), Universitätsklinikum Essen, Essen, Germany; MRC Cyclotron Unit, Imperial College School of Medicine, Hammersmith Hospital, London, UK (P.C., O.R.); Department of Physiology, Medical College of Wisconsin, Milwaukee (W.C.); Centro di Fisiologia Clinica, Ospedale Maggiore IRCCS, Milano, Italy (L.G.); Kardiologie, Universitätsspital Bern, Switzerland (O.H.); and Cattedra di Cardiologia, Università Federico II, Napoli, Italy (C.I.).

Correspondence to Prof Dr Gerd Heusch, Direktor der Abteilung für Pathophysiologie, Zentrum für Innere Medizin, Universitätsklinikum Essen, Hufelandstraße 55, 45122 Essen, Germany. E-mail gerd.heusch{at}uni-essen.de

Abstract

Abstract—The use of quantitative coronary angiography, combined with Doppler and PET, has recently been directed at the study of -adrenergic coronary vasomotion in humans. Confirming prior animal experiments, there is no evidence of -adrenergic coronary constrictor tone at rest. Again confirming prior experiments, responses to -adrenoceptor activation are augmented in the presence of coronary endothelial dysfunction and atherosclerosis, involving both ₁- and ₂-adrenoceptors in epicardial conduit arteries and microvessels. Such augmented -adrenergic coronary constriction is observed during exercise and coronary interventions, and it is powerful enough to induce myocardial ischemia and limit myocardial function. Recent studies indicate a genetic determination of ₂-adrenergic coronary constriction.

Key Words: coronary disease • ischemia • microcirculation • nervous system • receptors, adrenergic, alpha

Under normal circumstances, small coronary arteries and arterioles with a diameter of <300 µm are the principal determinants of coronary vascular resistance.¹ These vessels receive autonomic innervation, and their diameter is altered by activation of these nerves.² In animal experiments, there is little -adrenergic coronary vasomotor tone at rest, and the increase in coronary blood flow during sympathetic activation is only somewhat blunted. When the coronary circulation, however, is impaired by hypercholesterolemia,³ endothelial dysfunction,⁴ exhaustion of autoregulation,⁵ or severe coronary stenosis,^{6 7} -adrenergic vasoconstriction becomes unrestrained and powerful enough to reduce coronary blood flow and initiate myocardial ischemia.⁸ Both ₁- and ₂-adrenoceptors mediate coronary vasoconstriction, and there is a gradient with ₁-adrenoceptors more predominant in larger vessels and a reverse gradient with ₂-adrenoceptors more predominant in the microcirculation.^{5 9} Surprisingly, isolated coronary arterioles of a size that constricts in vivo to ₁-adrenoceptor activation are unresponsive in vitro,¹⁰ and cardiomyocytes on ₁-adrenergic activation release endothelin, which causes arteriolar constriction.¹¹

In the past, the study of -adrenergic coronary vasoconstriction in humans has been limited by a lack of adequate techniques to quantify coronary blood flow and myocardial perfusion. In the last decade, quantitative coronary angiography has allowed quantification of the diameter of coronary arteries to 0.5 mm. Study of the human coronary microcirculation is indirect¹² and relies on parameters such as coronary flow velocity, measured invasively with Doppler flow probes, or myocardial blood flow, quantified noninvasively with PET.¹³ Recently, these techniques have become widely available and directed toward the study of -adrenergic coronary vasoconstriction in humans. Moreover, selective ₁- and ₂-agonists and -antagonists are now available for clinical use. The antagonist approach is used to study the endogenous -adrenergic coronary vasoconstriction at rest or during sympathetic activation. Different maneuvers to elicit sympathetic activation, eg, exercise, cold pressor test, mental stress, or sympathoexcitatory reflexes, may differ in their recruitment of -adrenergic coronary vasoconstriction and in the concomitant activation of other mechanisms. The agonist approach is used to study the effect of selective -adrenoceptor agonists on coronary blood flow, myocardial perfusion, and contractile function during different physiological and pathophysiological conditions. Also, a genetic determination of -adrenergic coronary constrictor responses can now be analyzed in humans; a polymorphism in the genes encoding for a G-protein subunit explains part of the interindividual variation in -adrenergic coronary vasoconstriction.^13A

-Adrenergic Coronary Constrictor Tone in Subjects With Normal Coronary Angiograms

Ideally, resting -adrenergic constrictor tone is investigated (1) with intracoronary administration of an -antagonist, (2) with ß-blockade to avoid direct and indirect (metabolic) ß-adrenergic dilation in response to augmented norepinephrine release after presynaptic -blockade, and (3) under true resting conditions in the absence of changes in systemic hemodynamics. A few studies only come close to such rigid requirements.

Using quantitative coronary angiography and intracoronary Doppler, Hodgson et al¹⁴ studied patients with angiographically normal coronary arteries and cardiac transplant recipients. With ß-blockade, intracoronary infusion of the nonselective -antagonist phentolamine induced minimal changes in epicardial diameter and coronary resistance in both normally innervated and denervated patients, indicating negligible resting -adrenergic tone.¹⁴ Similarly, neither epicardial diameter nor coronary blood flow velocity was altered by intracoronary phentolamine in another study in cardiac transplant recipients.¹⁵ Although the subjects in the above studies had normal coronary angiograms, they had clinical indication of coronary catheterization, ie, chest pain. More recently, myocardial perfusion was measured with PET and ¹⁵O-labeled water in normal volunteers without signs, symptoms, or risk factors of coronary artery disease, and no difference in resting perfusion before and after 10 days of oral treatment with the selective ₁-antagonist doxazosin was found.¹⁶ Thus, there is no significant -adrenergic coronary constrictor tone at rest, confirming prior experiments.¹⁷

The response of angiographically normal coronary arteries to sympathetic activation by the cold pressor test,^{15 18 19 20 21 22} mental stress,^{23 24} or exercise^{15 18 25 26} is vasodilation of both epicardial coronary arteries^{15 18 21 22 23 24 25 26 27} and microvessels.^{15 18 21 22 23 24 27} In contrast to animal studies,²⁸ there is no evidence that vasodilation is limited by -adrenergic coronary vasoconstriction and consequently enhanced by -blockade in healthy humans.^{15 26}

The limitation of coronary reserve by -adrenergic coronary vasoconstriction is controversial. Using quantitative coronary angiography and Doppler in patients with normal coronary angiogram and in cardiac transplant recipients, Hodgson et al¹⁴ found that coronary reserve, as recruited by intracoronary papaverine, was not increased by intracoronary -blockade with and without additional ß-blockade. In contrast, in normal volunteers, oral treatment with doxazosin increased the dipyridamole-recruited coronary reserve as assessed with PET,¹⁶ consistent with findings in conscious dogs.²⁹ Part of the increase in coronary reserve with doxazosin could be attributed to increased circulating catecholamines in response to dipyridamole.³⁰

Using the selective ₂-antagonist yohimbine in the presence of ß-blockade, Indolfi et al³¹ found no changes in epicardial diameter and coronary blood flow velocity in patients with atypical chest pain but angiographically normal coronary arteries. Baumgart et al,³² using intracoronary infusion of the selective ₁-agonist methoxamine at increasing doses, observed no vasoconstriction of normal epicardial coronary arteries (as confirmed by intravascular ultrasound) or resistive vessels. Although it did not affect epicardial coronary artery diameter, intracoronary infusion of the selective ₂-agonist BHT 933 induced a dose-dependent microvascular constriction.

Thus, there appears to be no -adrenergic coronary constrictor tone at rest but possibly a limitation of coronary reserve. The constrictor response of the normal coronary circulation during sympathetic activation is mediated by ₂-adrenoceptors and mainly affects the microcirculation.

Enhanced -Adrenergic Vasoconstriction in Patients With Endothelial Dysfunction and Risk Factors

Intact endothelium opposes -adrenergic vasoconstriction, and both shear stress and activation of endothelial ₂-adrenoceptors contribute to the inhibition of -adrenergic vasoconstriction in the experimental setting.^{4 33}

Apparently, early stages of endothelial dysfunction and atherosclerosis already impair coronary dilator and predispose to constrictor responses. Exercise-induced dilation of angiographically normal epicardial vessels is largely attenuated in the presence of hypercholesterolemia³⁴ or hypertension,³⁵ and flow-mediated epicardial dilation is blunted in smokers.³⁶ Nabel et al²¹ first used quantitative coronary angiography and Doppler to compare changes in epicardial diameter and coronary blood flow in angiographically normal vessels with those in vessels with mild and more advanced atherosclerosis during the cold pressor test. They found a progressive reversal from vasodilation to vasoconstriction during the cold pressor test in both epicardial and resistive vessels with increasing severity of atherosclerosis. Zeiher et al²⁷ confirmed the loss of dilation of atherosclerotic epicardial and resistive vessels during the cold pressor test and found that the vasomotor response closely correlated with that to intracoronary acetylcholine. Patients with endothelial dysfunction in one protocol tended to experience exercise-induced ischemia during another protocol, as judged by thallium scintigraphy and anginal symptoms.³⁷ With intracoronary infusion of the selective ₁-agonist phenylephrine, a more pronounced coronary constriction was documented in mildly atherosclerotic epicardial segments that also constricted to acetylcholine, demonstrating the opposing influences of -adrenergic coronary constriction and endothelium-mediated coronary vasodilation.³⁸

Whether heart failure predisposes to enhanced -adrenergic coronary vasoconstriction is not clear. However, neither ₁- nor ₂-adrenoceptors in the peripheral circulation are downregulated in patients with heart failure.³⁹ Clearly, impairment of endothelial function and integrity even in early stages predisposes the human coronary circulation to enhanced -adrenergic vasoconstriction during sympathetic activation.

Enhanced -Adrenergic Vasoconstriction in Patients With Established Coronary Artery Disease

Recent studies using quantitative coronary angiography and Doppler confirm prior studies using coronary sinus thermodilution or xenon-133 clearance that found an increase in coronary resistance in patients with coronary artery disease during the cold pressor test,^{19 20 40} which was prevented by intravenous phentolamine¹⁹ or intravenous trimazosin, a selective ₁-antagonist.⁴⁰ Mental stress also induces dilation of normal and constriction of atherosclerotic epicardial and resistive vessels.^{23 24} Finally, smoking increases coronary resistance in patients with coronary artery disease, and this effect is counteracted by intravenous phentolamine.⁴¹

Most of the above studies that observed constrictor responses either did not report on signs and symptoms of ischemia or reported angina in only a minority of patients with coronary artery disease.^{19 20 24} Also, in most of these studies in which the cold pressor test or mental stress was used to induce sympathetic activation, there was no evidence of the -adrenergic nature of the observed vasoconstriction, but intracoronary phentolamine induced a greater decrease in coronary resistance than placebo during mental stress.²³ In patients with coronary artery disease, intracoronary infusion of the selective ₂-antagonist yohimbine with concomitant ß-blockade increased coronary sinus norepinephrine levels and reduced both epicardial diameter and coronary blood flow velocity, possibly because of enhanced ₁-adrenoceptor activation.³¹ An increase in coronary vascular resistance index in response to intravenous norepinephrine was found in patients with coronary artery disease.⁴² Baumgart et al,³² using intracoronary infusion of the selective ₁-agonist methoxamine at increasing doses in patients with coronary artery disease, reported constriction of both epicardial and resistive coronary vessels. Intracoronary infusion of the selective ₂-agonist BHT 933 did not induce constriction of normal but did induce constriction of atherosclerotic epicardial segments (the Figure). The decrease in coronary blood flow by BHT 933 in normal vessels was enhanced in the presence of atherosclerosis and was sufficient to induce net myocardial lactate production and ECG signs of ischemia,³² supporting prior studies in anesthetized⁶ and conscious dogs.⁷ In summary, coronary atherosclerosis unmasks ₁-adrenergic coronary constriction and augments ₂-adrenergic coronary constriction, which can precipitate myocardial ischemia.

View larger version (86K): [in this window] [in a new window]   Figure 1. Top left, Baseline angiogram; top right, epicardial response to 10 mg BHT 933; bottom left, ECG in response to BHT 933 and verapamil; bottom right, gradual decrease in intracoronary flow velocity after BHT 933.

Exercise-Induced Stenosis Constriction

In the early 1980s, the concept of dynamic coronary stenosis was introduced,^{43 44} which proposed that a stenotic coronary segment with an eccentric plaque and an adjacent wall region retaining vasomotor function might undergo active critical narrowing during sympathetic activation. With respect to more recent findings on the predisposition of vessels with endothelial dysfunction and atherosclerosis to undergo -adrenergic coronary vasoconstriction, stenosis constriction can be viewed as an extreme variant of this process. Isometric exercise (handgrip) decreased the angiographically determined minimal luminal area and induced angina in some patients,⁴⁵ an effect that was also elicited by combined propranolol and epinephrine,⁴⁴ supporting the -adrenergic nature of the observed stenosis constriction.

Stenosis constriction is also induced by dynamic exercise (supine bicycle) in patients with coronary artery disease and associated with angina in 2 of 3 patients studied.²⁵ The vasomotor nature of stenosis constriction during exercise is evidenced by its reversal with nitroglycerin,^{25 45} but its -adrenergic nature became evident only recently. In patients with coronary artery disease, intracoronary phentolamine, without and with ß-blockade, had no effect on epicardial cross-sectional area at rest but reversed the exercise-induced vasoconstriction of the stenotic segment into vasodilation.²⁶

-Adrenergic Coronary Vasoconstriction During Interventions

A series of recent studies has related epicardial coronary vasoconstriction that has been reported early after PTCA^{46 47} to -adrenergic activation.^{48 49 50 51 52} Gregorini et al⁴⁸ observed a constrictor response not only of the culprit segment and a distal segment of the vessel that underwent PTCA but also of the nonmanipulated control vessel. This vasoconstriction was abolished by intracoronary (at the coronary ostium) phentolamine. With ß-blockade, phentolamine still reversed constriction of the proximal segments of the culprit and control vessels but not of the respective distal segments. The selective ₂-antagonist yohimbine also attenuated the observed epicardial vasoconstriction, although only partially at the stenosis level.⁴⁸ Phentolamine with and without ß-blockade and yohimbine also reversed the decrease in coronary blood flow, but only phentolamine without ß-blockade caused a significant increase in coronary blood flow in the culprit vessel. Using a somewhat different protocol, Indolfi et al⁴⁹ compared epicardial vasomotion in control patients undergoing PTCA to that in patients pretreated with intracoronary (subselectively at the stenosis) phentolamine; phentolamine prevented constriction distal to the site of PTCA but not in the control segment. These findings were interpreted as evidence of a cardio-cardiac sympathoexcitatory reflex initiated by coronary stretch and/or myocardial ischemia and resulting in -adrenergic coronary vasoconstriction, as previously demonstrated in experiments.^{53 54} A significant vasoconstriction after successful PTCA was also found in the forearm circulation and was prevented by regional phentolamine. Because this -adrenergic forearm vasoconstriction was not accompanied by increased heart rate or arterial pressure, it possibly originated from the same thoracic spinal reflex as the -adrenergic coronary vasoconstriction and did not reflect a generalized adrenergic activation.⁵⁵

Gregorini et al⁵⁰ extended their studies to patients undergoing rotational atherectomy and PTCA; intracoronary infusion of the selective ₁-antagonist urapidil after atherectomy or PTCA reversed the observed decrease in epicardial diameter, and pretreatment with urapidil prevented any decrease in diameter. Subsequently, they also studied the consequences of PTCA-induced reflex -adrenergic coronary vasoconstriction on myocardial contractile function by transesophageal echocardiography.^{51 52} Intracoronary phentolamine and intravenous urapidil again reversed the decreases in the diameter of the distal poststenotic and control vessels and in coronary blood flow; they also reversed the observed decreases in systolic wall thickening in the previously ischemic and nonischemic myocardium.⁵¹ Finally, in patients with recent acute myocardial infarction and subsequent thrombolysis who then underwent PTCA and stent implantation, intracoronary phentolamine and intravenous urapidil reversed the observed -adrenergic vasoconstriction and reduction in systolic wall thickening in both the infarct-related and non–infarct-related artery territories; the improvements seen with urapidil were slightly attenuated by concomitant ß-blockade.⁵²

In carefully controlled clinical trials, although in a small number of patients, no benefit from prazosin in terms of angina, nitroglycerin use, and ECG changes was found in patients with Prinzmetal’s variant angina,^{56 57} a finding that did not support an important role of -adrenergic coronary constriction in this syndrome. A role of ₁-adrenergic coronary vasoconstriction in syndrome X, ie, in patients with normal coronary angiogram but exercise-induced chest pain and ECG alterations, was previously hypothesized, because doxazosin increased the dipyridamole-recruited coronary reserve in some patients. However, in 7 of 10 patients, dipyridamole-induced chest pain persisted.⁵⁸ In a subsequent double-blind randomized study, no difference in dipyridamole-recruited coronary reserve was found in patients with syndrome X treated with doxazosin versus placebo, and the flow reserve in syndrome X patients was comparable with that in normal volunteers.^58A

Exercise duration is prolonged with oral phentolamine,⁵⁹ and exercise-induced ST-segment depression and angina are reduced by intracoronary phentolamine⁶⁰ in patients with chronic stable angina. Oral treatment with the selective ₁-antagonist indoramin also improved exercise capacity and reduced ST-segment depression,⁶¹ although intracoronary indoramin was less effective than phentolamine in one study⁶² and oral indoramin did not reduce exercise-induced ST-segment depression in another study,⁶³ suggesting a predominant role of ₂-adrenergic poststenotic coronary vasoconstriction in exercise-induced ischemia, as previously demonstrated in dogs.^{6 7}

To what extent epicardial and microvascular circulation were affected by -blockade in these studies remains unclear. Larger, controlled trials looking at the effect of -blockade in patients with chronic stable angina are lacking and are probably worthwhile only with agents that do not block presynaptic ₂-adrenoceptors and thus do not increase norepinephrine release but are nevertheless effective at postsynaptic ₂-adrenoceptors, which appear more important than ₁-adrenoceptors in mediating -adrenergic coronary vasoconstriction. Such requirements are well met by calcium antagonists that may counteract -adrenergic coronary constriction in both the experimental⁶⁴ and clinical setting.⁶⁵

Perspective

Studies in the catheterization laboratory or using PET have established the existence of -adrenergic coronary constriction in humans and confirmed prior experimental studies. Importantly, the role of -adrenergic constriction during the cold pressor test, mental stress, and isometric and dynamic exercise, as well as coronary interventions, has been clearly demonstrated. The value of -antagonism in daily ischemic scenarios is less clear.

Further progress in imaging technique (better spatial resolution in PET, echo contrast) will also permit study of -adrenergic coronary constrictor influences on transmural blood flow distribution⁶⁶ in humans. Further progress is also expected from recent studies demonstrating a genetic determination of -adrenergic coronary constriction. A polymorphism in the gene encoding for the Gß3 subunit of G proteins that is associated with alternative splicing, enhanced signal transduction, and hypertension⁶⁷ also induces pronounced supersensitivity to ₂-adrenergic coronary constriction.^13A Future randomized, placebo-controlled studies should clarify the value of -antagonists in the treatment of various forms of ischemic heart disease, such as chronic stable angina or morning angina.

Acknowledgments

This manuscript goes back to a joint initiative of the Working Groups on Function and Coronary Circulation of the European Society of Cardiology.

References

1. Chilian WM, Eastham CL, Layne SM, Marcus ML. Small vessel phenomena in the coronary microcirculation: phasic intramyocardial perfusion and coronary microvascular dynamics. Prog Cardiovasc Dis. 1988;31:17–38.[Medline] [Order article via Infotrieve]

2. Chilian WM, Layne SM, Eastham CL, Marcus ML. Heterogeneous microvascular coronary -adrenergic vasoconstriction. Circ Res. 1989;64:376–388.[Abstract/Free Full Text]

3. Rosendorff C, Hoffman JIE, Verrier ED, Rouleau J, Boerboom LE. Cholesterol potentiates the coronary artery response to norepinephrine in anesthetized and conscious dogs. Circ Res. 1981;48:320–329.[Abstract/Free Full Text]

4. Jones CJH, DeFily DV, Patterson JL, Chilian WM. Endothelium-dependent relaxation competes with ₁ - and ₂-adrenergic constriction in the canine epicardial coronary microcirculation. Circulation. 1993;87:1264–1276.[Abstract/Free Full Text]

5. Chilian WM. Functional distribution of ₁- and ₂-adrenergic receptors in the coronary microcirculation. Circulation. 1991;84:2108–2122.[Abstract/Free Full Text]

6. Heusch G, Deussen A. The effects of cardiac sympathetic nerve stimulation on the perfusion of stenotic coronary arteries in the dog. Circ Res. 1983;53:8–15.[Free Full Text]

7. Seitelberger R, Guth BD, Heusch G, Lee JD, Katayama K, Ross J Jr. Intracoronary ₂-adrenergic receptor blockade attenuates ischemia in conscious dogs during exercise. Circ Res. 1988;62:436–442.[Abstract/Free Full Text]

8. Heusch G. -Adrenergic mechanisms in myocardial ischemia. Circulation. 1990;81:1–13.[Abstract/Free Full Text]

9. Heusch G, Deussen A, Schipke J, Thämer V. ₁- and ₂-adrenoceptor-mediated vasoconstriction of large and small canine coronary arteries in vivo. J Cardiovasc Pharmacol. 1984;6:961–968.[Medline] [Order article via Infotrieve]

10. Jones CHJ, Kuo L, Davis MJ, Chilian WM. -Adrenergic responses of isolated canine coronary microvessels. Basic Res Cardiol. 1995;90:61–69.[Medline] [Order article via Infotrieve]

11. Tiefenbacher CP, DeFily DV, Chilian WM. Requisite role of cardiac myocytes in coronary ₁-adrenergic constriction. Circulation. 1998;98:9–12.[Abstract/Free Full Text]

12. Maseri A. Coronary vasoconstriction: visible and invisible. N Engl J Med. 1991;325:1579–1580.[Medline] [Order article via Infotrieve]

13. De Silva R, Camici PG. Role of positron emission tomography in the investigation of human coronary circulatory function. Cardiovasc Res. 1994;28:1595–1612.[Medline] [Order article via Infotrieve]

13. Baumgart D, Naber C, Haude M, Oldenburg O, Erbel R, Heusch G, Siffert W. G protein ß3 subunit 825T allele and enhanced coronary vasoconstriction on 2-adrenoceptor activation. Circ Res.. 1999;85:965–969.[Abstract/Free Full Text]

14. Hodgson JM, Cohen MD, Szentpetery S, Thames MD. Effects of regional - and ß-blockade on resting and hyperemic coronary blood flow in conscious, unstressed humans. Circulation. 1989;79:797–809.[Abstract/Free Full Text]

15. Aptecar E, Dupouy P, Benvenuti C, Mazzucotelli J-P, Teiger E, Geschwind H, Castaigne A, Loisance D, Dubois-Rande J-L. Sympathetic stimulation overrides flow-mediated endothelium-dependent epicardial coronary vasodilation in transplant patients. Circulation. 1996;94:2542–2550.[Abstract/Free Full Text]

16. Lorenzoni R, Rosen SD, Camici PG. Effect of ₁-adrenoceptor blockade on resting and hyperemic myocardial blood flow in normal humans. Am J Physiol. 1996;40:H1302–H1306.

17. Chilian WM, Boatwright RB, Shoji T, Griggs DM. Evidence against significant resting sympathetic coronary vasoconstrictor tone in the conscious dog. Circ Res. 1981;49:866–876.[Abstract/Free Full Text]

18. Dubois-Rande J-L, Dupouy P, Aptecar E, Bhatia A, Teiger E, Hittinger L, Berdeaux A, Castaigne A, Geschwind H. Comparison of the effects of exercise and cold pressor test on the vasomotor response of normal and atherosclerotic coronary arteries and their relation to the flow-mediated mechanism. Am J Cardiol. 1996;76:467–473.

19. Mudge GH, Grossman W, Mills RM Jr, Lesch M, Braunwald E. Reflex increase in coronary vascular resistance in patients with ischemic heart disease. N Engl J Med. 1976;295:1333–1337.[Abstract]

20. Mudge GH, Goldberg S, Gunther S, Mann T, Grossman W. Comparison of metabolic and vasoconstrictor stimuli on coronary vascular resistance in man. Circulation. 1979;59:544–550.[Free Full Text]

21. Nabel EG, Ganz P, Gordon JB, Alexander RW, Selwyn AP. Dilation of normal and constriction of atherosclerotic coronary arteries caused by the cold pressor test. Circulation. 1988;77:43–52.[Abstract/Free Full Text]

22. Zeiher AM, Drexler H, Wollschläger H, Just H. Modulation of coronary vasomotor tone in humans: progressive endothelial dysfunction with different early stages of coronary atherosclerosis. Circulation. 1991;83:391–401.[Abstract/Free Full Text]

23. Dakak N, Quyyumi AA, Eisenhofer G, Goldstein DS, Cannon RO III. Sympathetically mediated effects of mental stress on the cardiac microcirculation of patients with coronary artery disease. Am J Cardiol. 1995;76:125–130.[Medline] [Order article via Infotrieve]

24. Yeung AC, Vekshtein VI, Krantz DS, Vita JA, Ryan TJ Jr, Ganz P, Selwyn AP. The effect of atherosclerosis on the vasomotor response of coronary arteries to mental stress. N Engl J Med. 1991;325:1551–1556.[Abstract]

25. Gage JE, Hess OM, Murakami T, Ritter M, Grimm J, Krayenbuehl HP. Vasoconstriction of stenotic coronary arteries during dynamic exercise in patients with classic angina pectoris: reversibility by nitroglycerin. Circulation. 1986;73:865–876.[Abstract/Free Full Text]

26. Julius BK, Vassalli G, Mandinov L, Hess OM. -Adrenoceptor blockade prevents exercise-induced vasoconstriction of stenotic coronary arteries. J Am Coll Cardiol. 1999;33:1499–1505.[Abstract/Free Full Text]

27. Zeiher AM, Drexler H, Wollschläger H, Just H. Endothelial dysfunction of the coronary microvasculature is associated with impaired coronary blood flow regulation in patients with early atherosclerosis. Circulation. 1991;84:1–10.[Abstract/Free Full Text]

28. Chilian WM, Harrison DG, Haws CW, Snyder WD, Marcus ML. Adrenergic coronary tone during submaximal exercise in the dog is produced by circulating catecholamines: evidence for adrenergic denervation supersensitivity in the myocardium but not in coronary vessels. Circ Res. 1986;58:68–82.[Abstract/Free Full Text]

29. Vlahakes GJ, Baer RW, Uhlig PN, Verrier ED, Bristow JD, Hoffman JIE. Adrenergic influence in the coronary circulation of conscious dogs during maximal vasodilation with adenosine. Circ Res. 1982;51:371–384.[Free Full Text]

30. Lucarini AR, Picano E, Marini C, Favilla S, Salvetti A, Distante A. Activation of sympathetic tone during dipyridamole test. Chest. 1992;102:444–447.[Abstract/Free Full Text]

31. Indolfi C, Piscione F, Villari B, Russolillo E, Rendina V, Golino P, Condorelli M, Chiariello M. Role of ₂-adrenoceptors in normal and atherosclerotic human coronary circulation. Circulation. 1992;86:1116–1124.[Abstract/Free Full Text]

32. Baumgart D, Haude M, Goerge G, Liu F, Ge J, Große-Eggebrecht C, Erbel R, Heusch G. Augmented -adrenergic constriction of atherosclerotic human coronary arteries. Circulation. 1999;99:2090–2097.[Abstract/Free Full Text]

33. Tesfamariam B, Cohen RA. Inhibition of adrenergic vasoconstriction by endothelial cell shear stress. Circ Res. 1988;63:720–725.[Abstract/Free Full Text]

34. Seiler C, Hess OM, Buechi M, Suter TM, Krayenbuehl HP. Influence of serum cholesterol and other coronary risk factors on vasomotion of angiographically normal coronary arteries. Circulation. 1993;88:2139–2148.[Abstract/Free Full Text]

35. Frielingsdorf J, Seiler C, Kaufmann P, Vassalli G, Suter T, Hess OM. Normalization of abnormal coronary vasomotion by calcium antagonists in patients with hypertension. Circulation. 1996;93:1380–1387.[Abstract/Free Full Text]

36. Zeiher AM, Schächinger V, Minners J. Long-term cigarette smoking impairs endothelium-dependent coronary arterial vasodilator function. Circulation. 1995;92:1094–1100.[Abstract/Free Full Text]

37. Zeiher AM, Krause T, Schächinger V, Minners J, Moser E. Impaired endothelium-dependent vasodilation of coronary resistance vessels is associated with exercise-induced myocardial ischemia. Circulation. 1995;91:2345–2352.[Abstract/Free Full Text]

38. Vita JA, Treasure CB, Yeung AC, Vekshtein VI, Fantasia GM, Fish RD, Ganz P, Selwyn AP. Patients with evidence of coronary endothelial dysfunction as assessed by acetylcholine infusion demonstrate marked increase in sensitivity to constrictor effects of catecholamines. Circulation. 1992;85:1390–1397.[Abstract/Free Full Text]

39. Indolfi C, Maione AG, Volpe M, Rapacciuolo A, Esposito G, Ceravolo R, Rendina V. Forearm vascular responsiveness to ₁- and ₂-adrenoceptor stimulation in patients with congestive heart failure. Circulation. 1994;90:17–22.[Abstract/Free Full Text]

40. Kern MJ, Horowitz JD, Ganz P, Gaspar J, Colucci WS, Lorell BH, Barry WH, Mudge GH. Attenuation of coronary vascular resistance by selective ₁-adrenergic blockade in patients with coronary artery disease. J Am Coll Cardiol. 1985;5:840–846.[Abstract]

41. Winniford MD, Wheelan KR, Kremers MS, Ugolini V, van der Berg E Jr, Niggemann EH, Jansen DE, Hillis LD. Smoking-induced coronary vasoconstriction in patients with atherosclerotic coronary artery disease: evidence for adrenergically mediated alterations in coronary artery tone. Circulation. 1986;73:662–667.[Abstract/Free Full Text]

42. White CW, Chierchia S, Wilson RF, Porter A, Maseri A. Coronary vasoconstrictor effects of norepinephrine in patients with coronary atherosclerosis: evidence from selective measurement of coronary flow velocity. J Am Coll Cardiol. 1985;5:432. Abstract.

43. Rafflenbeul W, Lichtlen PR. Zum Konzept der "dynamischen" Koronarstenose. Z Kardiol. 1982;71:439–444.[Medline] [Order article via Infotrieve]

44. Brown BG, Bolson EL, Dodge HT. Dynamic mechanisms in human coronary stenosis. Circulation. 1984;70:917–922.[Abstract/Free Full Text]

45. Brown BG, Lee AB, Bolson EL, Dodge HT. Reflex constriction of significant coronary stenosis as a mechanism contributing to ischemic left ventricular dysfunction during isometric exercise. Circulation. 1984;70:18–24.[Abstract/Free Full Text]

46. Fischell TA, Bausback KN, McDonald TV. Evidence for altered epicardial coronary artery autoregulation as a cause of distal coronary vasoconstriction after successful percutaneous transluminal coronary angioplasty. J Clin Invest. 1990;86:575–584.

47. El-Tamimi H, Davies GJ, Hackett D, Sritara P, Bertrand O, Crea F, Maseri A. Abnormal vasomotor changes early after coronary angioplasty. Circulation. 1991;84:1198–1202.[Abstract/Free Full Text]

48. Gregorini L, Fajadet J, Robert G, Cassagneau B, Bernis M, Marco J. Coronary vasoconstriction after percutaneous transluminal coronary angioplasty is attenuated by antiadrenergic agents. Circulation. 1994;90:895–907.[Abstract/Free Full Text]

49. Indolfi C, Piscione F, Rapacciuolo A, Esposito G, Esposito N, Ceravolo R, Di Lorenzo E, Maione AG, Condorelli M, Chiariello M. Coronary artery vasoconstriction after successful single angioplasty of the left anterior descending artery. Am Heart J. 1994;128:858–864.[Medline] [Order article via Infotrieve]

50. Gregorini L, Marco J, Bernies M, Cassagneau B, Pomidossi G, Anguissola GB, Fajadet J. The alpha-1 adrenergic blocking agent urapidil counteracts postrotational atherectomy "elastic recoil" where nitrates have failed. Am J Cardiol. 1997;79:1100–1103.[Medline] [Order article via Infotrieve]

51. Gregorini L, Marco J, Palombo C, Kozàkovà M, Anguissola GB, Cassagneau B, Bernies M, Distante A, Marco I, Fajadet J, Zanchetti A. Postischemic left ventricular dysfunction is abolished by alpha-adrenergic blocking agents. J Am Coll Cardiol. 1998;31:992–1001.[Abstract/Free Full Text]

52. Gregorini L, Marco J, Kozàkovà M, Palombo C, Anguissola GB, Marco I, Bernies M, Cassagneau B, Distante A, Bossi IM, Fajadet J, Heusch G. Alpha-adrenergic blockade improves recovery of myocardial perfusion and function after coronary stenting in patients with acute myocardial infarction. Circulation. 1999;99:482–490.[Abstract/Free Full Text]

53. Malliani A, Schwartz PJ, Zanchetti A. A sympathetic reflex elicited by experimental coronary occlusion. Am J Physiol. 1969;217:703–709.

54. Heusch G, Deussen A, Thämer V. Cardiac sympathetic nerve activity and progressive vasoconstriction distal to coronary stenoses: feed-back aggravation of myocardial ischemia. J Auton Nerv Syst. 1985;13:311–326.[Medline] [Order article via Infotrieve]

55. Indolfi C, Piscione F, Ceravolo R, Maione AG, Focaccio A, Rao MA, Esposito G, Condorelli M, Chiariello M. Limb vasoconstriction after successful angioplasty of the left anterior descending coronary artery. Circulation. 1995;92:2109–2112.[Abstract/Free Full Text]

56. Robertson RM, Bernard YD, Carr RK, Robertson D. Alpha-adrenergic blockade in vasotonic angina: lack of efficacy of specific alpha-1-receptor blockade with prazosin. J Am Coll Cardiol. 1983;2:1146–1150.[Abstract]

57. Winniford MD, Filipchuk N, Hillis LD. Alpha-adrenergic blockade for variant angina: a long-term, double-blind, randomized trial. Circulation. 1983;67:1185–1188.[Abstract/Free Full Text]

58. Camici PG, Marraccini P, Gistri R, Salvadori PA, Sorace O, L’Abbate A. Adrenergically mediated coronary vasoconstriction in patients with syndrome X. Cardiovasc Drugs Ther. 1994;8:221–226.[Medline] [Order article via Infotrieve]

58. Rosen SD, Lorenzoni R, Kaski JC, Foale RA, Camici PG. Effect of alpha1-adrenoreceptor blockade on coronary vasodilator reserve in cardiac syndrome X. J Cardiovasc Pharmacol.. 1999;34:554–560.[Medline] [Order article via Infotrieve]

59. Gould L, Reddy GV, Gombrecht RF. Oral phentolamine in angina pectoris. Jpn Heart J. 1973;14:393–397.[Medline] [Order article via Infotrieve]

60. Berkenboom GM, Abramowicz M, Vandermoten P, Degre SG. Role of alpha- adrenergic coronary tone in exercise-induced angina pectoris. Am J Cardiol. 1986;57:195–198.[Medline] [Order article via Infotrieve]

61. Collins P, Sheridan D. Improvement in angina pectoris with alpha adrenoceptor blockade. Br Heart J. 1985;53:488–492.[Abstract/Free Full Text]

62. Berkenboom G, Unger P. -Adrenergic coronary constriction in effort angina. In: Heusch G, Ross J, eds. Adrenergic Mechanisms in Myocardial Ischemia. Steinhopff-Veolug; Darmstadt: 1991.

63. Niveditha Y, Bishop N, Boyle RM, Stroker JB, Mary DASG. Changes in myocardial ischemia during isosorbide dinitrate or indoramin therapy in patients with stable angina using relations between the ST segment and heart rate. Int J Cardiol. 1988;19:341–354.[Medline] [Order article via Infotrieve]

64. Heusch G, Guth BD, Seitelberger R, Ross J Jr. Attenuation of exercise-induced myocardial ischemia in dogs with recruitment of coronary vasodilator reserve by nifedipine. Circulation. 1987;75:482–490.[Abstract/Free Full Text]

65. Gunther S, Green L, Muller JE, Mudge GH, Grossman W. Prevention by nifedipine of abnormal coronary vasoconstriction in patients with coronary artery disease. Circulation. 1981;63:849–855.[Abstract/Free Full Text]

66. Baumgart D, Ehring T, Kowallik P, Guth BD, Krajcar M, Heusch G. The impact of -adrenergic coronary vasoconstriction on the transmural myocardial blood flow distribution during humoral and neuronal adrenergic activation. Circ Res. 1993;73:869–886.[Abstract/Free Full Text]

67. Siffert W, Rosskopf D, Siffert G, Busch S, Moritz A, Erbel R, Sharma AM, Ritz E, Wichman H-E, Jakobs KH, Horsthemke B. Association of human G-protein ß3 subunit variant with hypertension. Nat Genet. 1998;18:45–48.[Medline] [Order article via Infotrieve]

This article has been cited by other articles:

				B. C. Jensen, P. M. Swigart, M.-E. Laden, T. DeMarco, C. Hoopes, and P. C. Simpson The alpha-1D Is the predominant alpha-1-adrenergic receptor subtype in human epicardial coronary arteries. J. Am. Coll. Cardiol., September 22, 2009; 54(13): 1137 - 1145. [Abstract] [Full Text] [PDF]

				P. G. Camici and O. E. Rimoldi The Clinical Value of Myocardial Blood Flow Measurement J. Nucl. Med., July 1, 2009; 50(7): 1076 - 1087. [Abstract] [Full Text] [PDF]

				E. Barbato Role of adrenergic receptors in human coronary vasomotion Heart, April 1, 2009; 95(7): 603 - 608. [Full Text] [PDF]

				F. Crea, P. G. Camici, R. De Caterina, and G. A. Lanza CHAPTER 17 Chronic Ischaemic Heart Disease ESC Textbook of Cardiovascular Medicine, January 1, 2009; 2(1): med-9780199566990-chapter - med-9780199566990-chapter. [Abstract] [Full Text] [PDF]

				C. Kolyva, B.-J. Verhoeff, J. A. E. Spaan, J. J. Piek, and M. Siebes Increased diastolic time fraction as beneficial adjunct of {alpha}1-adrenergic receptor blockade after percutaneous coronary intervention Am J Physiol Heart Circ Physiol, November 1, 2008; 295(5): H2054 - H2060. [Abstract] [Full Text] [PDF]

				G. Heusch, A. Skyschally, P. Gres, P. van Caster, D. Schilawa, and R. Schulz Improvement of regional myocardial blood flow and function and reduction of infarct size with ivabradine: protection beyond heart rate reduction Eur. Heart J., September 2, 2008; 29(18): 2265 - 2275. [Abstract] [Full Text] [PDF]

				D. J. Duncker and R. J. Bache Regulation of Coronary Blood Flow During Exercise Physiol Rev, July 1, 2008; 88(3): 1009 - 1086. [Abstract] [Full Text] [PDF]

				T. C. Sichrovsky, S. Mittal, and J. S. Steinberg Dexmedetomidine Sedation Leading to Refractory Cardiogenic Shock Anesth. Analg., June 1, 2008; 106(6): 1784 - 1786. [Abstract] [Full Text] [PDF]

				G. Heusch and R. Schulz The role of heart rate and the benefits of heart rate reduction in acute myocardial ischaemia Eur. Heart J. Suppl., September 1, 2007; 9(suppl_F): F8 - F14. [Abstract] [Full Text] [PDF]

				K. M. J. Marques, M. J. van Eenige, H. J. Spruijt, N. Westerhof, J. Twisk, C. A. Visser, and F. C. Visser The diastolic flow velocity-pressure gradient relation and dpv50 to assess the hemodynamic significance of coronary stenoses Am J Physiol Heart Circ Physiol, December 1, 2006; 291(6): H2630 - H2635. [Abstract] [Full Text] [PDF]

				J. Rieber, A. Huber, I. Erhard, S. Mueller, M. Schweyer, A. Koenig, T. M. Schiele, K. Theisen, U. Siebert, S. O. Schoenberg, et al. Cardiac magnetic resonance perfusion imaging for the functional assessment of coronary artery disease: a comparison with coronary angiography and fractional flow reserve Eur. Heart J., June 2, 2006; 27(12): 1465 - 1471. [Abstract] [Full Text] [PDF]

				C. Schmidt, F. Hinder, H. Van Aken, G. Theilmeier, C. Bruch, S. P. Wirtz, H. Burkle, T. Guhs, M. Rothenburger, and E. Berendes The Effect of High Thoracic Epidural Anesthesia on Systolic and Diastolic Left Ventricular Function in Patients with Coronary Artery Disease Anesth. Analg., June 1, 2005; 100(6): 1561 - 1569. [Abstract] [Full Text] [PDF]

				E. Nygard, K. F. Kofoed, J. Freiberg, S. Holm, J. Aldershvile, K. Eliasen, and H. Kelbaek Effects of High Thoracic Epidural Analgesia on Myocardial Blood Flow in Patients With Ischemic Heart Disease Circulation, May 3, 2005; 111(17): 2165 - 2170. [Abstract] [Full Text] [PDF]

				D. Merkus, A. K. Brzezinska, C. Zhang, S. Saito, and W. M. Chilian Cardiac myocytes control release of endothelin-1 in coronary vasculature Am J Physiol Heart Circ Physiol, May 1, 2005; 288(5): H2088 - H2092. [Abstract] [Full Text] [PDF]

				G. Heusch and K. R. Sipido Myocardial Hibernation: A Double-Edged Sword Circ. Res., April 30, 2004; 94(8): 1005 - 1007. [Full Text] [PDF]

				T. H. Schindler, E. U. Nitzsche, M. Olschewski, I. Brink, M. Mix, J. Prior, A. Facta, M. Inubushi, H. Just, and H. R. Schelbert PET-Measured Responses of MBF to Cold Pressor Testing Correlate with Indices of Coronary Vasomotion on Quantitative Coronary Angiography J. Nucl. Med., March 1, 2004; 45(3): 419 - 428. [Abstract] [Full Text]

				T H Schindler, E Nitzsche, N Magosaki, I Brink, M Mix, M Olschewski, U Solzbach, and H Just Regional myocardial perfusion defects during exercise, as assessed by three dimensional integration of morphology and function, in relation to abnormal endothelium dependent vasoreactivity of the coronary microcirculation Heart, May 1, 2003; 89(5): 517 - 526. [Abstract] [Full Text] [PDF]

				A. Snapir, J. Mikkelsson, M. Perola, A. Penttila, M. Scheinin, and P. J. Karhunen Variation in the alpha2B-adrenoceptorgene as a risk factor for prehospitalfatal myocardial infarction and sudden cardiac death J. Am. Coll. Cardiol., January 15, 2003; 41(2): 190 - 194. [Abstract] [Full Text] [PDF]

				G. Heusch Emerging importance of alpha-adrenergic coronary vasoconstriction in acute coronary syndromes and its genetic background J. Am. Coll. Cardiol., January 15, 2003; 41(2): 195 - 196. [Full Text] [PDF]

				M. Ruscazio, R. Montisci, P. Colonna, C. Caiati, L. Chen, G. Lai, M. Cadeddu, R. Pirisi, and S. Iliceto Detection of coronary restenosis aftercoronary angioplasty by contrast-enhanced transthoracic echocardiographic Doppler assessment of coronary flow velocity reserve J. Am. Coll. Cardiol., September 4, 2002; 40(5): 896 - 903. [Abstract] [Full Text] [PDF]

				J. Pekkanen, A. Peters, G. Hoek, P. Tiittanen, B. Brunekreef, J. de Hartog, J. Heinrich, A. Ibald-Mulli, W. G. Kreyling, T. Lanki, et al. Particulate Air Pollution and Risk of ST-Segment Depression During Repeated Submaximal Exercise Tests Among Subjects With Coronary Heart Disease: The Exposure and Risk Assessment for Fine and Ultrafine Particles in Ambient Air (ULTRA) Study Circulation, August 20, 2002; 106(8): 933 - 938. [Abstract] [Full Text] [PDF]

				D. Sun, A. Huang, S. Mital, M. R. Kichuk, C. C. Marboe, L. J. Addonizio, R. E. Michler, A. Koller, T. H. Hintze, and G. Kaley Norepinephrine Elicits {beta}2-Receptor-Mediated Dilation of Isolated Human Coronary Arterioles Circulation, July 30, 2002; 106(5): 550 - 555. [Abstract] [Full Text] [PDF]

				D. Lucini, G. Norbiato, M. Clerici, and M. Pagani Hemodynamic and Autonomic Adjustments to Real Life Stress Conditions in Humans Hypertension, January 1, 2002; 39(1): 184 - 188. [Abstract] [Full Text] [PDF]

				T.-M. Lee, S.-F. Su, W.-Y. Suo, C.-Y. Lee, M.-F. Chen, Y.-T. Lee, and C.-H. Tsai Distension of urinary bladder induces exaggerated coronary constriction in smokers with early atherosclerosis Am J Physiol Heart Circ Physiol, December 1, 2000; 279(6): H2838 - H2845. [Abstract] [Full Text] [PDF]

This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Heusch, G. Articles by Rimoldi, O. Search for Related Content PubMed PubMed Citation Articles by Heusch, G. Articles by Rimoldi, O. Related Collections Acute coronary syndromes Autonomic, reflex, and neurohumoral control of circulation Coronary circulation